BrackgroundCurrent treatments for Alzheimer’s disease (AD) have a limited clinical response and methods, such as repetitive transcranial magnetic stimulation (rTMS), are being studied as possible treatments for the clinical symptoms with positive results. However, there is still seldom information on the type of rTMS protocols that deliver the best clinical improvement in AD.ObjetiveTo compare the clinical response between a simple stimulation protocol on the left dorsolateral prefrontal cortex (lDLPFC) against a complex protocol using six regions of interest.Methods19 participants were randomized to receive any of the protocols. The analysis of repeated measures evaluated the change.ResultsBoth protocols were equally proficient at improving cognitive function, behavior and functionality after 3 weeks of treatment, and the effects were maintained for 4 weeks more without treatment.ConclusionWe suggest rTMS on the lDLPFC could be enough to provide a clinical response, and the underlying mechanisms should be studied.
Research Data Related to this SubmissionData set https://zenodo.org/record/1409808#.W5E3oCOZPIF
Patterns of reduced cortical thickness and striatum pathological morphology in cocaine addictionThis dataset includes all the data and scripts needed to reproduce the analysis and results on the manuscript "Patterns of reduced cortical thickness and striatum pathological morphology in cocaine addiction" (link). The brain data is not raw, as T1w were not defaced. We will do so in the near future for version 2.0. Instead we include only the "output/thickness" files used in the final analysis. For the use of raw T1w images, please contact the main author EAGV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.